MA40969A - Peptide homodimérique pour le traitement du diabète et des maladies liées - Google Patents
Peptide homodimérique pour le traitement du diabète et des maladies liéesInfo
- Publication number
- MA40969A MA40969A MA040969A MA40969A MA40969A MA 40969 A MA40969 A MA 40969A MA 040969 A MA040969 A MA 040969A MA 40969 A MA40969 A MA 40969A MA 40969 A MA40969 A MA 40969A
- Authority
- MA
- Morocco
- Prior art keywords
- diabetes
- treatment
- related diseases
- homodimeric peptide
- homodimeric
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1420445.7A GB2532426B (en) | 2014-11-18 | 2014-11-18 | Therapeutic homodimer and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40969A true MA40969A (fr) | 2021-04-28 |
Family
ID=52248504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA040969A MA40969A (fr) | 2014-11-18 | 2015-11-16 | Peptide homodimérique pour le traitement du diabète et des maladies liées |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20180015136A1 (fr) |
| EP (1) | EP3220939B1 (fr) |
| JP (1) | JP6693969B2 (fr) |
| KR (1) | KR20170083064A (fr) |
| CN (1) | CN107206048B (fr) |
| AU (1) | AU2015348673B2 (fr) |
| BR (1) | BR112017010346A2 (fr) |
| CA (1) | CA2967140C (fr) |
| CY (1) | CY1124859T1 (fr) |
| DK (1) | DK3220939T3 (fr) |
| EA (1) | EA034876B1 (fr) |
| ES (1) | ES2886001T3 (fr) |
| GB (1) | GB2532426B (fr) |
| HK (1) | HK1223287A1 (fr) |
| IL (1) | IL252349B (fr) |
| MA (1) | MA40969A (fr) |
| MX (1) | MX2017006278A (fr) |
| SG (1) | SG11201703757PA (fr) |
| WO (1) | WO2016079066A1 (fr) |
| ZA (1) | ZA201703580B (fr) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ566245A (en) * | 2005-08-11 | 2012-04-27 | Matossian Rogers Arpi | Tcr-v-beta related peptides for treatment and diagnosis of autoimmune disease |
| GB0516527D0 (en) * | 2005-08-11 | 2005-09-21 | Arpi Matossian Rogers | Peptides |
-
2014
- 2014-11-18 GB GB1420445.7A patent/GB2532426B/en active Active
-
2015
- 2015-11-16 US US15/527,904 patent/US20180015136A1/en not_active Abandoned
- 2015-11-16 DK DK15795157.5T patent/DK3220939T3/da active
- 2015-11-16 CN CN201580073803.2A patent/CN107206048B/zh active Active
- 2015-11-16 KR KR1020177014562A patent/KR20170083064A/ko active IP Right Grant
- 2015-11-16 AU AU2015348673A patent/AU2015348673B2/en active Active
- 2015-11-16 SG SG11201703757PA patent/SG11201703757PA/en unknown
- 2015-11-16 ES ES15795157T patent/ES2886001T3/es active Active
- 2015-11-16 BR BR112017010346A patent/BR112017010346A2/pt not_active Application Discontinuation
- 2015-11-16 CA CA2967140A patent/CA2967140C/fr active Active
- 2015-11-16 WO PCT/EP2015/076712 patent/WO2016079066A1/fr active Application Filing
- 2015-11-16 JP JP2017544990A patent/JP6693969B2/ja active Active
- 2015-11-16 EA EA201791103A patent/EA034876B1/ru unknown
- 2015-11-16 MX MX2017006278A patent/MX2017006278A/es unknown
- 2015-11-16 MA MA040969A patent/MA40969A/fr unknown
- 2015-11-16 EP EP15795157.5A patent/EP3220939B1/fr active Active
-
2016
- 2016-10-05 HK HK16111584.1A patent/HK1223287A1/zh unknown
-
2017
- 2017-05-17 IL IL252349A patent/IL252349B/en unknown
- 2017-05-24 ZA ZA2017/03580A patent/ZA201703580B/en unknown
-
2020
- 2020-11-10 US US17/094,192 patent/US20210060118A1/en active Pending
-
2021
- 2021-09-30 CY CY20211100850T patent/CY1124859T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB2532426A (en) | 2016-05-25 |
| CY1124859T1 (el) | 2022-11-25 |
| NZ731655A (en) | 2020-09-25 |
| ZA201703580B (en) | 2018-08-29 |
| SG11201703757PA (en) | 2017-06-29 |
| MX2017006278A (es) | 2017-10-24 |
| ES2886001T3 (es) | 2021-12-16 |
| HK1223287A1 (zh) | 2017-07-28 |
| JP6693969B2 (ja) | 2020-05-13 |
| AU2015348673B2 (en) | 2019-01-03 |
| GB201420445D0 (en) | 2014-12-31 |
| CN107206048B (zh) | 2021-02-26 |
| WO2016079066A1 (fr) | 2016-05-26 |
| CN107206048A (zh) | 2017-09-26 |
| BR112017010346A2 (pt) | 2018-05-15 |
| EP3220939A1 (fr) | 2017-09-27 |
| KR20170083064A (ko) | 2017-07-17 |
| US20210060118A1 (en) | 2021-03-04 |
| AU2015348673A1 (en) | 2017-06-01 |
| CA2967140A1 (fr) | 2016-05-26 |
| IL252349A0 (en) | 2017-07-31 |
| EP3220939B1 (fr) | 2021-06-30 |
| DK3220939T3 (da) | 2021-08-30 |
| EA201791103A1 (ru) | 2017-09-29 |
| US20180015136A1 (en) | 2018-01-18 |
| GB2532426B (en) | 2016-11-02 |
| CA2967140C (fr) | 2021-09-21 |
| EA034876B1 (ru) | 2020-04-01 |
| IL252349B (en) | 2022-02-01 |
| JP2018500386A (ja) | 2018-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR22C1011I1 (fr) | Promedicaments de fumarates et leur utilisation pour le traitement de diverses maladies | |
| MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
| FR3046933B1 (fr) | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires | |
| EP3227330C0 (fr) | Polypeptides de liaison à tdp-43 utiles pour le traitement de maladies neurodégénératives | |
| MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
| MA41299A (fr) | Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite | |
| DK3197472T3 (da) | Rekombinante phe-frie proteiner til anvendelse i behandlingen af phenylketonuri | |
| MA47719A (fr) | Esketamine pour le traitement de la dépression | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| MA42999A (fr) | Polythérapie pour le traitement de malignités | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| MA44762A (fr) | Sémaglutide utilisé dans le traitement de maladies cardiovasculaires | |
| IL239629A0 (en) | History of benzylideneguanidine and therapeutic use for the treatment of diseases resulting from misfolding of proteins | |
| FR3017298B1 (fr) | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires | |
| DK3157522T3 (da) | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste | |
| MA53614A (fr) | Protéine pour le traitement de maladies inflammatoires | |
| DK3149049T3 (da) | Il-22 til anvendelse til behandling af stofskiftesygdomme | |
| GB201618424D0 (en) | Treatment of antibody mediated disease | |
| PL3348273T3 (pl) | Kompozycje na bazie ksyloglukanu i białek do leczenia zaburzeń jelitowych | |
| MA39950A (fr) | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie | |
| MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
| FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee | |
| DK3229827T3 (da) | Modificerede peptider og anvendelse deraf til behandling af kroniske inflammatoriske sygdomme | |
| PT3177599T (pt) | Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória | |
| FR3015285B1 (fr) | Formulation pour le traitement des cheveux |